Inclusion Criteria:

- Histologically confirmed locally advanced or metastatic gastric cancer.

- Measurable or evaluable disease.

- Measurable disease is defined as at least 1 unidimensionally measurable lesion ≥ 20
mm by conventional techniques or 1 bidimensionally measurable lesion ≥ 20 X 10 mm.
Lesions that are smaller or uni- or bidimensionally unmeasurable are considered as
evaluable disease.

- Previous adjuvant chemotherapy with Irinotecan, Oxaliplatin and/or 5-FU based
regimen. Patients who relapse within the first 6 months after the completion of
adjuvant treatment are not eligible for the study.

- Karnofsky performance status > 70%.

- Age ≥18 years.

- Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL), renal
(Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥ 100,000/mm3) function.

- Patients must be able to understand the nature of this study and give written
informed consent.

Exclusion Criteria:

- Active infection

- History of serious cardiac disease (unstable angina, congestive heart failure,
myocardial infarction within the previous 6 months, ventricular arrhythmias)

- Previous radiotherapy within the last 4 weeks or > 25% of bone marrow.

- Patients with CNS metastases

- Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction.

- Malnutrition or loss of > 10% of body weight during the last month.

- Peripheral neuropathy ≥ grade 2

- Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
cancer.

- Psychiatric illness or social situation that would preclude study compliance.

- Pregnant or lactating women.